Deep vein thrombosis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 15: | Line 15: | ||
===Anticoagulation=== | ===Anticoagulation=== | ||
{{main|Anticoagulation}} | {{main|Anticoagulation}} | ||
[[Anticoagulation]] is the usual treatment for DVT. In general, patients are initiated on a brief course (i.e., less than a week) of [[heparin]] treatment while they start on a 3- to 6-month course of [[warfarin]] (or related [[vitamin K]] inhibitors). [[Low molecular weight heparin]] (LMWH) is preferred, | [[Anticoagulation]] is the usual treatment for DVT. In general, patients are initiated on a brief course (i.e., less than a week) of [[heparin]] treatment while they start on a 3- to 6-month course of [[warfarin]] (or related [[vitamin K]] inhibitors). [[Low molecular weight heparin]] (LMWH) is preferred,[http://www.ncbi.nlm.nih.gov/pubmed/17261857] though unfractionated [[heparin]] is given in patients who have a contraindication to LMWH (e.g., renal failure or imminent need for invasive procedure). In patients who have had ''recurrent DVTs'' (two or more), anticoagulation is generally "life-long." The [[Cochrane Collaboration]] has meta-analyzed the risk and benefits of prolonged anti-coagulation.[http://www.ncbi.nlm.nih.gov/pubmed/16437432] | ||
An abnormal [[D-dimer]] level at the end of treatment might signal the need for continued treatment among patients with a first unprovoked proximal deep-vein thrombosis.<ref name="pmid17065639">{{cite journal |author=Palareti G, Cosmi B, Legnani C, ''et al'' |title=D-dimer testing to determine the duration of anticoagulation therapy |journal=N. Engl. J. Med. |volume=355 |issue=17 |pages=1780-9 |year=2006 |pmid=17065639 |doi=10.1056/NEJMoa054444}}</ref> | An abnormal [[D-dimer]] level at the end of treatment might signal the need for continued treatment among patients with a first unprovoked proximal deep-vein thrombosis.<ref name="pmid17065639">{{cite journal |author=Palareti G, Cosmi B, Legnani C, ''et al'' |title=D-dimer testing to determine the duration of anticoagulation therapy |journal=N. Engl. J. Med. |volume=355 |issue=17 |pages=1780-9 |year=2006 |pmid=17065639 |doi=10.1056/NEJMoa054444}}</ref> |
Revision as of 02:48, 24 August 2011
Editors-in-Chief: C. Michael Gibson, M.S., M.D. Associate Editor-In-Chief: Ujjwal Rastogi, MBBS [1]
Deep Vein Thrombosis Microchapters |
Diagnosis |
---|
Treatment |
Special Scenario |
Trials |
Case Studies |
Deep vein thrombosis medical therapy On the Web |
Risk calculators and risk factors for Deep vein thrombosis medical therapy |
Medical Therapy
Hospitalization
Treatment at home is an option according to a meta-analysis by the Cochrane Collaboration.[2] Hospitalization should be considered in patients with more than two of the following risk factors as these patients may have more risk of complications during treatment [3]
- bilateral DVT,
- Renal insufficiency,
- Body weight <70 kg,
- Recent immobility,
- Chronic heart failure
- Cancer
Anticoagulation
Anticoagulation is the usual treatment for DVT. In general, patients are initiated on a brief course (i.e., less than a week) of heparin treatment while they start on a 3- to 6-month course of warfarin (or related vitamin K inhibitors). Low molecular weight heparin (LMWH) is preferred,[4] though unfractionated heparin is given in patients who have a contraindication to LMWH (e.g., renal failure or imminent need for invasive procedure). In patients who have had recurrent DVTs (two or more), anticoagulation is generally "life-long." The Cochrane Collaboration has meta-analyzed the risk and benefits of prolonged anti-coagulation.[5]
An abnormal D-dimer level at the end of treatment might signal the need for continued treatment among patients with a first unprovoked proximal deep-vein thrombosis.[1]
Thrombolysis
Thrombolysis is generally reserved for extensive clot, e.g. an iliofemoral thrombosis. Although a meta-analysis of randomized controlled trials by the Cochrane Collaboration shows improved outcomes with thrombolysis,[2] there may be an increase in serious bleeding complications.
Compression stockings
Elastic compression stockings should be routinely applied "beginning within 1 month of diagnosis of proximal DVT and continuing for a minimum of 1 year after diagnosis".[3] Starting within one week may be more effective.[4] The stockings in almost all trials were stronger than routine anti-embolism stockings and created either 20-30 mm Hg or 30-40 mm Hg. Most trials used knee-high stockings. A meta-analysis of randomized controlled trials by the Cochrane Collaboration showed reduced incidence of post-phlebitic syndrome.[5] The number needed to treat is quite potent at 4 to 5 patients need to prevent one case of post-phlebitic syndrome.[6]
- ↑ Palareti G, Cosmi B, Legnani C; et al. (2006). "D-dimer testing to determine the duration of anticoagulation therapy". N. Engl. J. Med. 355 (17): 1780–9. doi:10.1056/NEJMoa054444. PMID 17065639.
- ↑ Watson L, Armon M. "Thrombolysis for acute deep vein thrombosis". Cochrane Database Syst Rev: CD002783. PMID 15495034.
- ↑
- ↑ Prandoni P, Lensing AW, Prins MH; et al. (2004). "Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial". Ann. Intern. Med. 141 (4): 249–56. PMID 15313740.
- ↑ Kolbach D, Sandbrink M, Hamulyak K, Neumann H, Prins M. "Non-pharmaceutical measures for prevention of post-thrombotic syndrome". Cochrane Database Syst Rev: CD004174. doi:10.1002/14651858.CD004174.pub2. PMID 14974060.
- ↑ Kakkos S, Daskalopoulou S, Daskalopoulos M, Nicolaides A, Geroulakos G (2006). "Review on the value of graduated elastic compression stockings after deep vein thrombosis". Thromb Haemost. 96 (4): 441–5. PMID 17003920.